Core Insights - XtalPi Holdings Limited (晶泰科技) has expanded its strategic collaboration with Pfizer to develop a next-generation molecular simulation platform aimed at accelerating new drug development [1][5] - The collaboration will enhance the efficiency, accuracy, and chemical space coverage of the molecular simulation platform, significantly speeding up the discovery and development of small molecule drugs [1][2] Company Overview - XtalPi was founded in 2015 by three physicists from MIT and operates as an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics [6] - The company provides drug and materials science R&D solutions and services to global companies across various industries, including pharmaceuticals, agricultural technology, energy, and cosmetics [6] Technological Advancements - The collaboration has resulted in the development of a high-precision force field (XtalPi Force Field, XFF) that outperforms leading commercial software in multiple R&D scenarios [2] - The molecular simulation platform can accurately predict small molecule geometries and perform high-precision affinity predictions through free energy perturbation (FEP) calculations, which are crucial for evaluating drug candidates [2] Future Applications - Following the upgrade, the teams will develop more precise predictive models tailored to Pfizer's proprietary chemical space, expanding the platform's applications in small molecule drug development [5] - XtalPi will localize its XFEP platform for Pfizer, covering the entire process from parameter customization to FEP calculations, aiming for higher precision, throughput, and user experience [5]